David M. Denton will join Pfizer as Chief Financial Officer and Executive Vice President effective May 2, 2022.
Denton will be a member of Pfizer’s Executive Leadership Team reporting to chairman and CEO, Albert Bourla. He joins Pfizer from Lowe’s Companies, Inc. where he served as CFO and Executive Vice President. Denton succeeds Frank D’Amelio, CFO and Executive Vice President, who recently announced his intention to leave Pfizer after a 15-year career. D’Amelio will remain in place through a transition period.
Denton has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. He will be a key thought partner to the Company’s CEO and Executive Leadership Team while overseeing every aspect of the Company’s financial management. He will be responsible for all corporate finance functions, including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.
Prior to joining Lowe's in 2018, Denton was CFP of CVS Health, where he was responsible for all aspects of their financial planning and management. He played a key role in CVS’s journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, Denton played a pivotal role in CVS’s acquisition of Aetna, structuring and negotiating the terms and financing for the transaction.
Before becoming CFO at CVS, Denton held several leadership roles, including senior vice president and controller/chief accounting officer. Prior to CVS, he was with the management consulting firm of Deloitte Touche Tohmatsu.
He earned a bachelor's degree in business administration from Kansas State University, USA and an MBA from the Babcock Graduate School of Management at Wake Forest University, USA. He serves on the board of Tapestry, Inc.
Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to CEO, Stéphane Bancel.
Gomez joins Moderna from Dentsply Sirona, Inc. (Nasdaq: XRAY) where he served as Executive Vice President & Chief Financial Officer since August 2019. At Dentsply Sirona, he was responsible for leading the global finance organization, including strategic finance, FP&A, Accounting, Treasury, Tax, Corporate Audit and Investor Relations, and the Information Technology function. In addition, Gomez was responsible for leading Dentsply Sirona's sustainability and ESG program.
Prior to Dentsply Sirona, Gomez spent 13 years at Cardinal Health, a Fortune 14 company, where he most recently served as CFO and previously held positions including Medical Segment CFO, Pharmaceutical Segment CFO, Corporate Treasurer and Corporate Controller. Prior to Cardinal Health, Gomez held positions at General Motors, including in New York City, Singapore, Belgium, and Brazil.
Gomez received his Master of Business Administration from the University of Hartford and his Bachelor of Science in electrical engineering from the National University of Colombia. Mr. Gomez serves on the Board of Directors for Xylem, Inc. and for Pear Therapeutics.
David Meline, Moderna's current CFO, came out of retirement in spring 2020 to help Moderna commercialize its COVID-19 vaccine. He goes back into retirement but will remain with the company as consultant to ensure a smooth transition.
BioIVT, a provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has appointed Jennifer Murphy as Senior Vice President of Global Commercial Operations.
She will be responsible for building and growing the global commercial programs for all BioIVT’s product lines and services.
Murphy joins BioIVT from Thermo Fisher Scientific where she held roles of increasing responsibility, progressing from account manager to area director and senior director to vice president of sales across five businesses in the Customer Channels, Specialty Diagnostics, and Life Sciences groups. She also served as the executive champion for the company’s Women's, African Heritage, and Working Parents Employee Resource Groups.
Prior to joining Thermo Fisher, Murphy spent 10 years as a medical technologist and clinical laboratory director for hospital and clinic systems in the Midwest.
She has a Bachelor of Science degree in Biology and Chemistry from the University of Wisconsin – Platteville and a Master of Business Administration with an emphasis in HealthCare Administration from the University of Phoenix.
Dr. Eliav Barr will become head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL): with Dr. Roy D. Baynes retiring in July.
As an oncologist and clinical development expert, Dr. Baynes spearheaded the development of Keytruda and ‘leaves an indelible mark on Merck, on oncology and on the lives of patients and their families’, says the company.
Dr. Baynes joined Merck in 2013. Under his leadership, Merck achieved more than 140 medicine and vaccine approvals globally across numerous therapeutic areas. Alongside Keytruda (pembrolizumab), this has included Welireg (belzutifan), Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine), Zepatier (elbasvir and grazoprevir), Lagevrio (molnupiravir), Zerbaxa (ceftolozane and tazobactam), Recarbrio (relebactam), Prevymis (letermovir), Bridion (sugammadex) among others and, in collaboration with AstraZeneca, Eisai and Bayer, the development of Lynparza (olaparib), Lenvima (lenvatinib) and Verquvo (vericiguat), respectively. He also led the expansion of Merck’s research and development in China and Japan.
Dr. Eliav Barr, is currently senior vice president, Global Clinical Development at Merck. During his more than two decades at the company, Dr. Barr has held positions of increasing responsibility including leadership roles in oncology and infectious diseases clinical development. Dr. Barr oversaw the company’s Vaccines/Infectious Disease area during a period of high productivity, including the development of novel therapies for chronic hepatitis C and HIV-1 infections. Most recently he led MRL’s Global Medical Affairs organization from 2018 to January 2022, significantly expanding Merck’s scientific engagement and implementation efforts in oncology, vaccines and more. In his new role Dr. Barr will lead all late-stage clinical development for Merck’s expansive human health portfolio and pipeline.
Dr. Barr is a cardiologist by training. He received his undergraduate degree from Penn State University and his medical degree from Sidney Kimmel Medical College, Thomas Jefferson University. He completed his Internal Medicine residency and Cardiology Fellowship at Johns Hopkins University, and subsequently pursued post-doctoral training at the University of Michigan. Prior to joining Merck in 1995, he held a faculty position at the University of Chicago. In 2019, he was a recipient of a Penn State Alumni Fellow Award for his dedication to the development of medicines and vaccines that treat and prevent infectious diseases.
CRO Alliance Pharma, a provider of bioanalytical services in the pharmaceutical and biopharmaceutical industry, has named Patrick Bennett as Chief Executive Officer.
Founded in 2008, is based in Malvern, PA just outside of Philadelphia. It specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies' drug discovery and development programs.
Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and Development at PPD Laboratories. Prior to PPD, Bennett served as the Director of Global Strategic Marketing at ThermoFisher Scientific, and at various executive level positions with Tandem Labs.
“Throughout his career, Patrick has developed broad bioanalytical expertise and established a strong reputation as a leader and innovator in laboratory operations. In his most recent roles, he established biomarker, cell and gene therapy operations, and a state-of-the-art bioanalytical lab in China,” says Alliance Pharma as it announces his appointment.
Frank Li, Founder of Alliance Pharma, is transitioning leadership to Bennett but will remain a key member of the Alliance team and serve as its President and on its Board of Directors.
Antoinette Gawin, CEO of Terumo Blood and Cell Technologies, has been appointed to parent company Terumo Corporation’s board as Group Managing Executive Officer.
The move comes as Terumo redefines its internal management system to support its expanding global operations, enhance competitiveness on a global scale, and achieve its five-year plan.
Terumo has shifted its business from predominantly “in Japan for Japan” to becoming a global healthcare company. Today, about 67% of Terumo’s revenue is generated outside of Japan, driven in part by the growth of Terumo Blood and Cell Technologies under Gawin’s leadership and the steady expansion of Terumo’s Cardiac and Vascular businesses.
The newly formed GMEO position will directly shape strategy across all Terumo operating entities. Gawin is the only female and only non-Japanese leader ever to serve in this capacity. She will continue participating in Terumo’s Executive Management Meeting (EMM) as a core member.
Gawin’s vision for Terumo Blood and Cell Technologies led to its successful return to growth, achieving $1bn sales in each of the last three years since she took the helm as CEO. She led the strategic shift to blood and beyond, including entrance to the source plasma industry and double-digit growth in the cell and gene therapy sector.
The company has also collaborated with Immunicom to launch breakthrough cancer immunotherapy treatment in Europe.
“Gawin is helping to shape customer environments with an ecosystem of automation, services and enterprise software that improves patient access to safe and adequate blood and cells. The company’s upgraded infrastructure and delivery system are foundational and were successfully tested during COVID-19 as production rapidly flexed to meet demand shifts and support the global collection of convalescent plasma,” says the company.